MedTrace Logo

Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

NCT03368170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-03-31

Study results available
· View outcomes & findings →

Summary

Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a side-effect frequently occurring with long-term levodopa treatment in patients with Parkinson's disease. In experimental animals mesdopetam potently reduced levodopa-induced involuntary movement without impairing the antiparkinsonian effect of levodopa.

The primary purpose of the trial is to investigate whether mesdopetam given as adjunctive treatment can reduce levodopa induced dyskinesia in patients with Parkinson's disease. The trial will also help to establish the most optimal dosing of the compound.

Conditions

  • Parkinson Disease

Interventions

DRUG

Mesdopetam (IRL790)

Mesdopetam (IRL790) capsule

Sponsors & Collaborators

  • The Clinical Trial Company

    collaborator INDUSTRY

  • Integrative Research Laboratories AB

    lead INDUSTRY

Principal Investigators

  • Camille Carroll, MD · Plymouth University Peninsula Schools of Medicine and Dentistry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-12
Primary Completion
2019-06-12
Completion
2019-06-12

Countries

  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03368170 on ClinicalTrials.gov